{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:06Z","timestamp":1789015686213,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01047-0","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T14:03:47Z","timestamp":1618495427000},"page":"673-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals"],"prefix":"10.1016","volume":"18","author":[{"given":"Daniel A.","family":"Wilkenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci L.","family":"Orbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-7722","authenticated-orcid":false,"given":"Jennifer H.","family":"Lingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01047-0_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jalz.2012.09.014","article-title":"Disclosure of amyloid imaging results to research participants: has the time come?","volume":"9","author":"Lingler","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/nmt.13.25","article-title":"Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues","volume":"3","author":"Roberts","year":"2013","journal-title":"Neurodegener Dis Manag."},{"key":"10.1007\/s13311-021-01047-0_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/bs.pmbts.2019.05.002","article-title":"Disclosure of amyloid PET scan results: a systematic review","volume":"165","author":"Kim","year":"2019","journal-title":"Prog Mol Biol Transl Sci."},{"key":"10.1007\/s13311-021-01047-0_bib4","doi-asserted-by":"crossref","unstructured":"Taswell C, Donohue C, Mastwyk MT, et al. Avoiding methodological bias in studies of amyloid imaging results disclosure. Alzheimers Res Ther. 2019;11.","DOI":"10.1186\/s13195-019-0495-y"},{"key":"10.1007\/s13311-021-01047-0_bib5","doi-asserted-by":"crossref","unstructured":"Grill JD, Raman R, Ernstrom K, et al. Short-term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. 2020.","DOI":"10.1001\/jamaneurol.2020.2734"},{"key":"10.1007\/s13311-021-01047-0_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jalz.2018.05.016","article-title":"Participant satisfaction with dementia prevention research: results from Home-Based Assessment trial","volume":"14","author":"Sano","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13195-017-0321-3","article-title":"Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context","volume":"9","author":"Vanderschaeghe","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"10.1007\/s13311-021-01047-0_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jalz.2017.01.001","article-title":"Patient and caregiver reactions to clinical amyloid imaging","volume":"13","author":"Grill","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib10","first-page":"748","article-title":"Safety of disclosing amyloid imaging results to MCI and AD patients","volume":"17","author":"Taswell","year":"2018","journal-title":"Ment Health Fam Med."},{"key":"10.1007\/s13311-021-01047-0_bib11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/alz.12129","article-title":"A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment","volume":"16","author":"Lingler","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jalz.2016.08.007","article-title":"A common challenge in older adults: classification, overlap, and therapy of depression and dementia","volume":"13","author":"Leyhe","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib13","doi-asserted-by":"crossref","unstructured":"Nowrangi MA, Lyketsos CG, Rosenberg PB. Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. Alz Res Therapy. 2015;7.","DOI":"10.1186\/s13195-015-0096-3"},{"key":"10.1007\/s13311-021-01047-0_bib14","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","article-title":"Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01047-0_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jalz.2016.01.009","article-title":"Ethical challenges in preclinical Alzheimer's disease observational studies and trials: results of the Barcelona summit","volume":"12","author":"Molinuevo","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08989620802388697","article-title":"Disclosure issues in neuroscience research","volume":"15","author":"Parker","year":"2008","journal-title":"Account Res."},{"key":"10.1007\/s13311-021-01047-0_bib17","unstructured":"The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical principles and guidelines for the protection of human subjects of research. In:1979."},{"key":"10.1007\/s13311-021-01047-0_bib18","series-title":"Principles of Biomedical Ethics","author":"Beauchamp","year":"2013"},{"key":"10.1007\/s13311-021-01047-0_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/medethics-2011-100207","article-title":"Forced to be free? Increasing patient autonomy by constraining it","volume":"40","author":"Levy","year":"2014","journal-title":"J Med Ethics."},{"key":"10.1007\/s13311-021-01047-0_bib20","series-title":"Hard luck: how luck undermines free will and moral responsibility","author":"Levy","year":"2011"},{"key":"10.1007\/s13311-021-01047-0_bib21","unstructured":"Budd Haeberlein S, O\u2019Gorman J, Chiao P, et al. Clinical development of aducanumab, an anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017:255\u2013263."},{"key":"10.1007\/s13311-021-01047-0_bib22","first-page":"1120","article-title":"What to tell cancer patients","volume":"175","author":"Oken","year":"1961","journal-title":"A study of medical attitudes. JAMA."},{"key":"10.1007\/s13311-021-01047-0_bib23","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jama.1979.03290350017012","article-title":"Changes in physicians' attitudes toward telling the cancer patient","volume":"241","author":"Novack","year":"1979","journal-title":"JAMA."},{"key":"10.1007\/s13311-021-01047-0_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1590\/S1980-57642009DN20400006","article-title":"Diagnostic disclosure in Alzheimer's disease: a review","volume":"2","author":"Raicher","year":"2008","journal-title":"Dement Neuropsychol."},{"key":"10.1007\/s13311-021-01047-0_bib25","unstructured":"FDA Accepts Biogen's Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review [press release]. August 7, 2020."},{"key":"10.1007\/s13311-021-01047-0_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/eahr.500024","article-title":"How do we really communicate? Challenging the assumptions behind informed consent interventions","volume":"41","author":"Cargill","year":"2019","journal-title":"Ethics Hum Res."},{"key":"10.1007\/s13311-021-01047-0_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/j.1538-7305.1948.tb01338.x","article-title":"A mathematical theory of communication","volume":"27","author":"Shannon","year":"1948","journal-title":"The Bell System Technical Journal."},{"key":"10.1007\/s13311-021-01047-0_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjsurg.2009.02.010","article-title":"Informed consent: how much and what do patients understand?","volume":"198","author":"Falagas","year":"2009","journal-title":"Am J Surg."},{"key":"10.1007\/s13311-021-01047-0_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0160-2527(82)90026-7","article-title":"The therapeutic misconception: informed consent in psychiatric research","volume":"5","author":"Appelbaum","year":"1982","journal-title":"Int J Law Psychiatry."},{"key":"10.1007\/s13311-021-01047-0_bib30","unstructured":"Schramm W. How communication works. In: Schramm W, ed. The Process and Effects of Mass Communication. Urbana: University of Illinois Press; 1954."},{"key":"10.1007\/s13311-021-01047-0_bib31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1525\/maq.2004.18.4.429","article-title":"Communication and miscommunication in informed consent to research","volume":"18","author":"Sankar","year":"2004","journal-title":"Med Anthropol Q."},{"key":"10.1007\/s13311-021-01047-0_bib32","doi-asserted-by":"crossref","unstructured":"Tversky A, Kahneman D. Rational choice and the framing of decisions. In: Multiple Criteria Decision Making and Risk Analysis Using Microcomputers. Springer; 1989:81\u2013126.","DOI":"10.1007\/978-3-642-74919-3_4"},{"key":"10.1007\/s13311-021-01047-0_bib33","unstructured":"Thaler RH, Sunstein CR. Nudge: Improving Decisions about Health, Wealth, and Happiness. Penguin; 2009."},{"key":"10.1007\/s13311-021-01047-0_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10823-008-9075-5","article-title":"Reexamining the relationships among dementia, stigma, and aging in immigrant Chinese and Vietnamese family caregivers","volume":"23","author":"Liu","year":"2008","journal-title":"J Cross Cult Gerontol."},{"key":"10.1007\/s13311-021-01047-0_bib35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/01.wad.0000190806.13126.55","article-title":"Cultural factors in dementia: perspectives from the anthropology of aging","volume":"19","author":"Henderson","year":"2005","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"10.1007\/s13311-021-01047-0_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1352\/1944-7558-121.2.121","article-title":"Communication services and supports for individuals with severe disabilities: guidance for assessment and intervention","volume":"121","author":"Brady","year":"2016","journal-title":"Am J Intellect Dev Disabil."},{"key":"10.1007\/s13311-021-01047-0_bib37","series-title":"Paternalism","author":"Dworkin","year":"2020"},{"key":"10.1007\/s13311-021-01047-0_bib38","doi-asserted-by":"crossref","unstructured":"Robin NH, Farmer MB. Chapter 8 - Ethical and legal issues. In: Robin NH, Farmer MB, eds. Pediatric Cancer Genetics: Elsevier Inc; 2017:93\u2013100.","DOI":"10.1016\/B978-0-323-48555-5.00008-9"},{"key":"10.1007\/s13311-021-01047-0_bib39","series-title":"Ethical Challenges in Oncology: Patient Care","author":"Gallagher","year":"2017"},{"key":"10.1007\/s13311-021-01047-0_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.NURSE.0000526899.00004.b9","article-title":"Responding to parents who refuse childhood immunizations","volume":"47","author":"Deem","year":"2017","journal-title":"Nursing."},{"key":"10.1007\/s13311-021-01047-0_bib41","doi-asserted-by":"crossref","first-page":"E1052","DOI":"10.1001\/amajethics.2018.1052","article-title":"Why health professionals should speak out against false beliefs on the internet","volume":"20","author":"Wu","year":"2018","journal-title":"AMA J Ethics."},{"key":"10.1007\/s13311-021-01047-0_bib42","first-page":"413","article-title":"Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure","volume":"10","author":"Lingler","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib43","series-title":"Stumbling on Happiness","author":"Gilbert","year":"2006"},{"key":"10.1007\/s13311-021-01047-0_bib44","unstructured":"The Genetic Information Nondiscrimination Act of 2008, (2008)."},{"key":"10.1007\/s13311-021-01047-0_bib45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1212\/WNL.0000000000000153","article-title":"Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet","volume":"82","author":"Arias","year":"2014","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01047-0_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3928\/19404921-20090401-04","article-title":"Diagnostic labels, stigma, and participation in research related to dementia and mild cognitive impairment","volume":"2","author":"Garand","year":"2009","journal-title":"Res Gerontol Nurs."},{"key":"10.1007\/s13311-021-01047-0_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3233\/JAD-200932","article-title":"A narrative review of Alzheimer's disease stigma","volume":"78","author":"Rosin","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"10.1007\/s13311-021-01047-0_bib48","unstructured":"Pagano B, Pagano E, Lundin SC. The Transparency Edge: How Credibility can Make or Break You in Business. McGraw Hill Professional; 2004."},{"key":"10.1007\/s13311-021-01047-0_bib49","unstructured":"McAllister WB, Botts J, Cozzens P, Marrs AW. Part II: Negotiating responsible historical transparency, 1920s to early 2000s. In. Toward \"Thorough, Accurate, and Reliable\": A History of the Foreign Relations of the United States Series. Washington, DC: Office of the Historian, US Department of State; 2015."},{"key":"10.1007\/s13311-021-01047-0_bib50","unstructured":"Responsible transparency: Getting ready for disclosure. Campaign launched to raise awareness of new financial disclosure rules [press release]. EFPIA2014."},{"key":"10.1007\/s13311-021-01047-0_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-017-0261-y","article-title":"Communicating mild cognitive impairment diagnoses with and without amyloid imaging","volume":"9","author":"Grill","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"10.1007\/s13311-021-01047-0_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","article-title":"Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants","volume":"7","author":"Harkins","year":"2015","journal-title":"Alzheimers Res Ther."},{"key":"10.1007\/s13311-021-01047-0_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-150985","article-title":"Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment","volume":"52","author":"Lingler","year":"2016","journal-title":"J Alzheimers Dis."},{"key":"10.1007\/s13311-021-01047-0_bib54","first-page":"243","article-title":"From information to follow-up: ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting","volume":"4","author":"Vanderschaeghe","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1007\/s13311-021-01047-0_bib55","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01047-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:59:04Z","timestamp":1761807544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011248"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01047-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01047-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}